Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fecal microbiota transplant (McMaster Children's Hospital)
- Development stage
- Unknown
- Lead developer
- McMaster Children's Hospital
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Rectal
01
Overview
Fecal microbiota transplant is an investigational biologic therapy being studied by McMaster Children's Hospital for the treatment of pediatric small intestinal bacterial overgrowth (SIBO). [1-3] The therapy consists of a complex mixture of live microorganisms derived from the stool of healthy pediatric donors, which is processed and prepared at McMaster Children's Hospital's local pediatric stool bank. [3-1] It is being evaluated in a Phase 1 pilot feasibility study (NCT05967871), which aims to assess its safety and efficacy in children aged 3 to 18 with SIBO. [11] The treatment is administered as an infusion directly into the gastrointestinal tract, either via a patient's existing enteral feeding tube or through an upper endoscopy into the duodenum. [2-2] The primary goal is to restore a healthy gut microbiome, correcting the dysbiosis associated with SIBO to alleviate symptoms. [3-4] The trial specifically targets patients at high risk for SIBO, including those with short bowel syndrome. [3-13]
- Other names
- FMTfecal microbiota from healthy donors
Beyond the preview
Go deeper on fecal microbiota transplant (McMaster Children's Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fecal microbiota transplant (McMaster Children's Hospital).